Ionis Pharmaceuticals Inc
IONS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000874015
In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 2 sales; 464 institutions reported holding it in 13F filings for Q3 2026, worth $7.66B in total; ARK Invest is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $381.4M (40.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 19, 2025 | Feb 21, 2024 | Feb 22, 2023 | Feb 24, 2022 |
| Revenue | $943.7M | $705.1M | $787.6M | $587.4M | $810.5M |
| Cost of revenue | $15.9M | $11.2M | $9.13M | $14.1M | $10.8M |
| Research and development | $915.6M | – | – | – | $638.2M |
| Selling, general and administrative | $393.9M | $267.5M | $232.6M | $150.3M | $186.3M |
| Operating income | -$381.7M | -$475.1M | -$353.7M | -$410.2M | -$30.2M |
| Interest expense | $17.3M | $17.0M | $12.7M | $8.12M | $9.35M |
| Income tax | $1.79M | -$6.17M | $32.3M | $11.7M | -$551.0K |
| Net income | -$381.4M | -$453.9M | -$366.3M | -$269.7M | -$28.6M |
| EPS, basic | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
| EPS, diluted | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
| Weighted shares, basic | 160.0M | 149.5M | 143.2M | 141.8M | 141.0M |
| Weighted shares, diluted | 160.0M | 149.5M | 143.2M | 141.8M | 141.0M |
| Margins and growth | |||||
| Operating margin | -40.4% | -67.4% | -44.9% | -69.8% | -3.7% |
| Net margin | -40.4% | -64.4% | -46.5% | -45.9% | -3.5% |
| Revenue growth, year over year | +33.8% | −10.5% | +34.1% | −27.5% | +11.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 19, 2025 | Feb 21, 2024 | Feb 22, 2023 | Feb 24, 2022 |
| Cash and equivalents | $372.3M | $242.1M | $399.3M | $276.5M | $869.2M |
| Short-term investments | $2.31B | $2.06B | $1.93B | $1.71B | – |
| Inventory | $10.0M | $12.5M | $28.4M | $22.0M | $24.8M |
| Total current assets | $2.99B | $2.62B | $2.64B | $2.20B | $2.35B |
| Property, plant and equipment | $123.0M | $94.3M | $71.0M | $74.3M | $178.1M |
| Intangible assets | – | – | – | – | $29.0M |
| Total assets | $3.52B | $3.00B | $2.99B | $2.53B | $2.61B |
| Accounts payable | $28.1M | $43.0M | $26.0M | $17.9M | $11.9M |
| Short-term debt | $432.1M | $165.0K | $157.0K | $151.0K | – |
| Total current liabilities | $781.6M | $309.3M | $448.1M | $311.6M | $240.6M |
| Long-term debt | $1.33B | $1.20B | $1.24B | $1.18B | – |
| Total liabilities | $3.03B | $2.42B | $2.60B | $1.96B | $1.84B |
| Shareholders' equity | $489.1M | $588.4M | $386.7M | $572.9M | $771.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 19, 2025 | Feb 21, 2024 | Feb 22, 2023 | Feb 24, 2022 |
| Operating cash flow | -$268.6M | -$500.9M | -$307.5M | -$274.4M | $30.8M |
| Capital expenditures | $51.4M | $45.3M | $23.8M | $15.7M | $12.0M |
| Free cash flow | -$320.0M | -$546.2M | -$331.3M | -$290.1M | $18.8M |
| Stock-based compensation | $133.9M | $130.2M | $105.8M | $100.3M | $120.7M |
| Share buybacks | – | – | – | $0 | $0 |
| Investing cash flow | -$277.8M | -$134.0M | -$214.1M | -$262.6M | $194.9M |
| Financing cash flow | $675.8M | $478.1M | $644.1M | -$55.3M | $245.9M |
| Net change in cash | $130.2M | -$157.2M | $122.8M | -$592.7M | $471.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 14.2% | 18.5% | 13.4% | 17.1% | 14.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 166.5M | +2.8% | SEC |
| Jul 23, 2026 | 166.2M | +4.3% | SEC |
| Apr 23, 2026 | 165.3M | +3.8% | SEC |
| Feb 19, 2026 | 165.2M | +3.9% | SEC |
| Oct 23, 2025 | 162.0M | +2.6% | SEC |
| Jul 24, 2025 | 159.4M | +9.0% | SEC |
| Apr 24, 2025 | 159.2M | +9.0% | SEC |
| Feb 13, 2025 | 159.0M | +9.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.